TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN–UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER CARCINOMA IN SITU: 1-YEAR DURABILITY AND PATIENT-REPORTED OUTCOMES FROM SUNRISE-1 | Publicación